Shanghai Chest Hospital

Running trials

• Not yet recruiting

  A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer

  NCT07896005· Phase 3· Source

• Not yet recruiting

  5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation for Pulmonary Malignancies

  NCT07830095· Source

• Recruiting

  Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma

  NCT07885319· Phase 1/2· Source

• Not yet recruiting

  DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Phase 1/2· Source

• Recruiting

  A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With TRUPULSE™ Generator in Persistent Atrial Fibrillation

  NCT07845682· Source

• Recruiting

  Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

  NCT07575672· Phase 3· Source

• Recruiting

  A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

  NCT07843940· Phase 1/2· Source

• Not yet recruiting

  A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy

  NCT07831863· Phase 3· Source

• Not yet recruiting

  Pulsed Field Ablation for the Treatment of Malignant Lung Tumors

  NCT07889297· Source

• Not yet recruiting

  A Phase 2 Study of ABSK043 Combined With Osimertinib

  NCT07710612· Phase 2· Source

• Not yet recruiting

  Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC

  NCT07698990· Source

• Recruiting

  Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer

  NCT07811752· Phase 2· Source

• Recruiting

  A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

  NCT07668752· Phase 3· Source

• Not yet recruiting

  JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

  NCT07714304· Source

• Recruiting

  Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.

  NCT07681245· Source

• Recruiting

  Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

  NCT07476287· Phase 2· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Source

• Not yet recruiting

  A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

  NCT07550842· Phase 1· Source

• Recruiting

  A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

  NCT07562581· Phase 2· Source

• Recruiting

  A Phase II Study of GC101 in NSCLC

  NCT07560111· Phase 2· Source

• Not yet recruiting

  Xuan Yin Ning Plus Bevacizumab for Malignant Pleural Effusion

  NCT07670338· Source

• Not yet recruiting

  Robotic-Assisted Bronchoscopy-Guided Synchronous Biopsy and Radiofrequency Ablation for Pulmonary Nodules

  NCT07545057· Source

• Recruiting

  A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

  NCT07593027· Phase 1/2· Source

• Recruiting

  Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

  NCT07231445· Phase 1· Source

• Recruiting

  JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

  NCT07518160· Phase 2· Source

• Recruiting

  A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC

  NCT07416695· Phase 1· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Source

• Recruiting

  RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC

  NCT07541521· Source

• Recruiting

  Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

  NCT07515027· Source

• Recruiting

  RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

  NCT07416474· Phase 3· Source

• Recruiting

  Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)

  NCT07564557· Source

• Recruiting

  Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment

  NCT07565532· Source

• Not yet recruiting

  A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy

  NCT07414927· Phase 1/2· Source

• Recruiting

  HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management

  NCT07402239· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Source

• Recruiting

  Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC

  NCT07528066· Source

• Recruiting

  Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer

  NCT07367516· Phase 1/2· Source

• Not yet recruiting

  A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study

  NCT07375979· Source

• Recruiting

  A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

  NCT07253142· Phase 2· Source

• Recruiting

  Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

  NCT07227298· Phase 1/2· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Source

• Not yet recruiting

  Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation

  NCT07331727· Source

• Not yet recruiting

  Left Ventricular Myocardial Work for Predicting Response to CRT

  NCT07319065· Source

• Not yet recruiting

  Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors

  NCT07282873· Phase 1/2· Source

• Active, not recruiting

  Renal Denervation Combined With Pulsed Field Ablation to Prevent Recurrence in Persistent Atrial Fibrillation

  NCT07320768· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

  NCT07362459· Phase 3· Source

• Recruiting

  A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure

  NCT07265349· Phase 1/2· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· Phase 3· Source

• Recruiting

  Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

  NCT07189455· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer123 recruiting
• Gastric and esophageal cancer17 recruiting
• Atrial fibrillation7 recruiting
• Childhood cancers7 recruiting
• Heart failure7 recruiting
• Colorectal cancer4 recruiting
• Neuroendocrine tumours4 recruiting
• Head and neck cancer2 recruiting
• High blood pressure2 recruiting
• Mesothelioma2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Sarcoma2 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Kidney cancer1 recruiting
• Melanoma1 recruiting
• Myasthenia gravis1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Impact of Different Lung Isolation Devices on Pharyngolaryngeal Injuries After Pulmonary Resection

  NCT07117539· Source

• Completed

  Shanghai Clinical Cohort - Esophageal Cancer

  NCT07312526· Source

• Completed

  Augmented Reality Assisted Lung Nodule Localization: a Multicentered, Prospective, Randomly Controlled, Non-inferiority Trial

  NCT06548451· Source

• Withdrawn

  A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)

  NCT05863819· Source

• Withdrawn

  Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

  NCT05338580· Phase 2· Source

• Completed

  A Randomized Controlled Study of Ablation Pursuing Atrial Fibrillation Termination as a Procedural Endpoint in Patients With Persistent Atrial Fibrillation

  NCT05921734· Source

• Completed

  Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05938920· Phase 2· Source

• Completed

  A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects

  NCT05895565· Phase 1· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Withdrawn

  EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

  NCT05411679· Phase 2· Source

• Completed

  JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

  NCT05664971· Phase 1/2· Source

• Completed

  PerAF: AF Termination vs Prespecified Ablation

  NCT06837441· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Source

• Terminated

  A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

  NCT05492045· Phase 1/2· Source

• Terminated

  A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

  NCT05501912· Phase 1· Source

• Completed

  Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

  NCT05420220· Phase 2· Source

• Completed

  Recurrent Persistent Atrial Fibrillation:In-situ Ablation Vs Extensive Ablation

  NCT06829446· Source

• Completed

  Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

  NCT05068427· Phase 2· Source

• Completed

  Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

  NCT05015608· Phase 3· Source

• Completed

  Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

  NCT04923945· Phase 3· Source

• Completed

  Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

  NCT04967079· Phase 1· Source

• Completed

  Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF

  NCT06660134· Source

• Recruiting

  Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

  NCT04886804· Phase 1· Source

• Completed

  Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

  NCT04732494· Phase 2· Source

• Completed

  Study to Evaluate D-1553 in Subjects With Lung Cancer

  NCT05383898· Phase 1/2· Source

• Completed

  Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04665856· Phase 3· Source

• Completed

  Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

  NCT04770688· Phase 1/2· Source

• Completed

  A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

  NCT04540211· Phase 3· Source

• Completed

  A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

  NCT04543617· Phase 3· Source

• Completed

  Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

  NCT04447118· Phase 3· Source

• Completed

  Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

  NCT04205812· Phase 3· Source

• Completed

  A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT04513925· Phase 3· Source

• Completed

  Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

  NCT04858958· Phase 1· Source

• Completed

  Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

  NCT04566432· Source

• Completed

  Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

  NCT04158440· Phase 3· Source

• Completed

  Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

  NCT04210115· Phase 3· Source

• Completed

  Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study

  NCT04676412· Phase 3· Source

• Completed

  A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

  NCT03940703· Phase 2· Source

• Completed

  Pre-Surgery If Needed for Oesophageal Cancer

  NCT03937362· Source

• Completed

  Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04005716· Phase 3· Source

• Completed

  A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

  NCT03909971· Phase 2· Source

• Completed

  A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

  NCT03596866· Phase 3· Source

• Completed

  Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

  NCT03829332· Phase 3· Source

• Completed

  Hybrid APC Therapy in Early Central Lung Neoplasms

  NCT03537378· Source

• Terminated

  A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

  NCT03866980· Phase 3· Source

• Completed

  Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

  NCT06613633· Source

• Completed

  A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

  NCT03456063· Phase 3· Source

• Completed

  Image Fusion of SPECT MPI and Fluoroscopy Venography to Guide LV Lead Placement for Improved CRT Response (GUIDE-CRT II)

  NCT03125720· Source

• Terminated

  To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

  NCT02974426· Phase 3· Source

• Completed

  A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

  NCT02838420· Phase 3· Source

Trial sites

• Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University1 trial
• Shanghai Chest Hospital240 trials
• Shanghai Chest Hospital /ID# 2109301 trial
• Shanghai Chest Hospital /ID# 2318971 trial
• Shanghai Chest Hospital /ID# 2691551 trial
• Shanghai Chest Hospital /ID# 2700361 trial
• Shanghai Chest Hospital /ID# 2752731 trial
• Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University1 trial
• Shanghai Chest Hospital, Shanghai, China1 trial
• Shanghai Chest Hospital, Shanghai Jiao Tong University3 trials
• Shanghai Chest Hospital, Shanghai Jiao Tong University Medicine of School2 trials
• Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine,3 trials
• Shanghai Chest Hospital, Shanghai, Recruiting1 trial
• Shanghai Chest Hospital (Site 0101)1 trial
• Shanghai Chest Hospital (Site 0112)2 trials
• Shanghai Chest Hospital (Site 0308)1 trial
• Shanghai Chest Hospital (Site 0501)1 trial
• Shanghai Chest Hospital (Site 0503)1 trial
• Shanghai Chest Hospital (Site 2229)1 trial
• Shanghai Chest Hospital (Site 2747)1 trial
• Shanghai Chest Hospital (Site 3100)1 trial
• Shanghai Chest Hospital (Site 3107)1 trial
• Shanghai Chest Hospital (Site 3207)1 trial
• Shanghai Chest Hospital (Site 5400)1 trial
• Shanghai Jiao Tong University School of Medicine, Shanghai Chest Hospital2 trials
• Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, P. R. China1 trial
• Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine1 trial
• The Chest Hospital of Shanghai1 trial
• Shanghai Chest Hospital1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer361 works · 207 trials
• Gastric and esophageal cancer40 works · 26 trials